Information Provided By:
Fly News Breaks for February 9, 2018
REGN
Feb 9, 2018 | 08:40 EDT
BMO Capital analyst Matthew Luchini lowered his price target on Regeneron to $398 and kept his Market Perform rating after the company's Q4 results. The analyst notes that while it was a "good quarter" with encouraging Eylea outperformance and Dupixent prescriptions, he is concerned about increased Dupixent access restrictions and the lack of use in less severe patients pressuring the company's forecasts. Luchini also cites the long term risk of an increasingly competitive VEGF market.
News For REGN From the Last 2 Days
REGN
REGN
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.